/VBIV

VBIV Stock - VBI Vaccines Inc.

Q: What is the analyst price target for VBIV?

Analyst price target information is not currently available for VBIV.

Q: What is VBIV's market cap?

Market capitalization information is not currently available for VBIV.

Healthcare|Biotechnology|NASDAQ

$0.07-50.87%

$0.07 (-50.87%) • Aug 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.07

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VBIV

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.17

52W High$1.35

52W Low$0.06

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$8.68M	$1.08M	$631,000	$1.06M	$2.22M
Gross Profit	$-5,815,000	$-10,194,000	$-10,139,000	$-8,107,000	$-5,683,000
Gross Margin	-67.0%	-942.1%	-1606.8%	-764.1%	-255.9%
Operating Income	$-55,311,000	$-81,820,000	$-68,032,000	$-43,617,000	$-52,399,000
Net Income	$-92,836,000	$-140,951,000	$-72,650,000	$-47,286,000	$-55,805,000
Net Margin	-1069.3%	-13026.9%	-11513.5%	-4456.7%	-2512.6%
EPS	$-5.96	$-16.37	$-8.55	$-6.50	$-14.02

Company Overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 2962.8% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 11th 2022	Raymond James	Downgrade	Outperform	$2← $5

Earnings History & Surprises

VBIV

Beat Rate

22%

Last 18 quarters

Avg Surprise

-103.9%

EPS vs Estimate

Beats / Misses

4/10

4 met exactly

Latest EPS

$-2.17

Q3 2024

EPS Surprise History

Q4 22

-12.5%

$-2.70vs$-2.40

Q1 23

-14.3%

$-2.40vs$-2.10

Q2 23

-7.0%

$-2.43vs$-2.27

Q3 23

-0.5%

$-2.17vs$-2.16

Q4 23

-171.4%

$-0.38vs$-0.14

Q1 24

-990.9%

$-2.40vs$-0.22

Q2 24

-3.8%

$-0.55vs$-0.53

Q3 24

-578.1%

$-2.17vs$-0.32

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	May 13, 2025	—	—	—	—
Q4 2024	Nov 12, 2024	$-0.32	—	—	—
Q3 2024	Aug 12, 2024	$-0.32	$-2.17	-578.1%	✗ MISS
Q2 2024	May 15, 2024	$-0.53	$-0.55	-3.8%	✗ MISS
Q1 2024	Mar 25, 2024	$-0.22	$-2.40	-990.9%	✗ MISS
Q4 2023	Nov 14, 2023	$-0.14	$-0.38	-171.4%	✗ MISS
Q3 2023	Aug 14, 2023	$-2.16	$-2.17	-0.5%	✗ MISS
Q2 2023	May 15, 2023	$-2.27	$-2.43	-7.0%	✗ MISS
Q1 2023	Mar 13, 2023	$-2.10	$-2.40	-14.3%	✗ MISS
Q4 2022	Nov 10, 2022	$-2.40	$-2.70	-12.5%	✗ MISS
Q3 2022	Aug 8, 2022	$-2.10	$-5.41	-157.6%	✗ MISS
Q2 2022	May 9, 2022	$-2.40	$-2.40	0.0%	= MET
Q1 2022	Mar 7, 2022	$-2.10	$-2.10	0.0%	= MET
Q4 2021	Nov 8, 2021	$-2.40	$-1.80	+25.0%	✓ BEAT
Q3 2021	Aug 2, 2021	$-2.40	$-2.10	+12.5%	✓ BEAT
Q2 2021	May 10, 2021	$-2.10	$-2.10	0.0%	= MET
Q1 2021	Mar 2, 2021	$-1.80	$-1.80	0.0%	= MET
Q4 2020	Nov 2, 2020	$-1.50	$-1.80	-20.0%	✗ MISS
Q3 2020	Jul 31, 2020	$-1.50	$-1.20	+20.0%	✓ BEAT
Q2 2020	May 6, 2020	$-2.10	$-1.50	+28.6%	✓ BEAT